What’s the current market cap for Intellia Therapeutics stock?

Intellia Therapeutics (NTLA) has a market cap of $1.9bn as of June 07, 2026.

What is the P/E ratio for Intellia Therapeutics stock?

The price to earnings (P/E) ratio for Intellia Therapeutics (NTLA) stock is 0 as of June 07, 2026.

Does Intellia Therapeutics stock pay dividends?

No, Intellia Therapeutics (NTLA) stock does not pay dividends to its shareholders as of June 07, 2026.

When is the next Intellia Therapeutics dividend payment date?

Intellia Therapeutics (NTLA) stock does not pay dividends to its shareholders.

What is the beta indicator for Intellia Therapeutics?

Intellia Therapeutics (NTLA) has a beta rating of 1.93. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Intellia Therapeutics stock | $NTLA Share Price

13:30

15:10

16:45

18:25

20:00

About Intellia Therapeutics

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Ticker

$NTLA

Sector

Health

Primary listing

NASDAQ

Employees

377

Headquarters

Cambridge, United States

Website

www.intelliatx.com

NTLA Metrics

BasicAdvanced

$1.9bn

-$3.52

1.93

What the Analysts think about NTLA

Analyst ratings (Buy, Hold, Sell) for Intellia Therapeutics stock.

Bulls say / Bears say

The FDA lifted a clinical hold on the MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) for hereditary ATTR amyloidosis with polyneuropathy, allowing dosing to resume and confirming confidence in the program's safety profile (Reuters)

Intellia began a rolling BLA submission for lonvoguran ziclumeran (lonvo-z) following positive Phase 3 HAELO topline results, positioning this one-time in vivo CRISPR therapy for a potential U.S. approval in H1 2027 (Reuters)

A Form 8-K filed May 11, 2026 reported $517.2 million in cash, cash equivalents, and marketable securities as of March 31, 2026, plus about $207 million in gross proceeds from an April equity offering, securing operating runway through at least 2028 (SEC Filing)

A separate MAGNITUDE Phase 3 trial in ATTR-CM is still on FDA hold, delaying the cardiomyopathy program and extending uncertainty for the broader ATTR franchise (Reuters)

A severe liver toxicity event led to suspension of the MAGNITUDE trials after a patient experienced Grade 4 transaminase elevations, sparking concerns over platform safety and raising questions about CRISPR off-target effects (Reuters)

NTLA stock declined 3% on April 27 despite positive Phase 3 HAELO data, highlighting investor doubt about commercial potential and valuation ahead of upcoming catalysts (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 20 May 2026.

NTLA Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

NTLA Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NTLA

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

A separate MAGNITUDE Phase 3 trial in ATTR-CM is still on FDA hold, delaying the cardiomyopathy program and extending uncertainty for the broader ATTR franchise (Reuters)

NTLA stock declined 3% on April 27 despite positive Phase 3 HAELO data, highlighting investor doubt about commercial potential and valuation ahead of upcoming catalysts (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 20 May 2026.